Company: PTPI
Filing Date: 2025-03-07
Form Type: PRE 14A
Source: 0001104659-25-021794
Chunk: 33

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-07
Form: PRE 14A
Chunk 33
---
 There can be no assurance that the Nasdaq staff would grant the Company’s request for continued
listing subsequent to any delisting notification. In the event of such a notification, the Company may appeal the Nasdaq staff’s
determination to delist its securities.

At the Company’s 2024
Annual Meeting of the Stockholders held on November 20, 2024, the stockholders of the Company approved a proposal to authorize the
Board to amend the Company’s Charter to effect a reverse stock split of Common Stock at a ratio between 1-for-2 and 1-for-25 with
the ultimate ratio to be determined by the Board in its sole discretion (the “Authorized Reverse Stock Split”). However, the
Board believes that the Authorized Reverse Stock Split is not sufficient to regain compliance with the Nasdaq Minimum Bid Price Rule.

On March 7, 2025, subject
to stockholder approval, the Board approved an amendment to our Charter to, at the discretion of the Board, effect the Reverse Stock Split
of the Common Stock at a ratio of 1-for-250 to 1-for-50, including shares held by the Company as treasury shares, with the exact ratio
within such range to be determined by the Board of the Company at its discretion. The primary goal of the Reverse Stock Split is to increase
the per share market price of our Common Stock to meet the minimum per share bid price requirements for continued listing on The Nasdaq
Capital Market. We believe that a range of Reverse Stock Split ratios provides us with the most flexibility to achieve the desired results
of the Reverse Stock Split. The Reverse Stock Split is not intended as, and will not have the effect of, a “going private transaction”
covered by Rule 13e-3 promulgated under the Exchange Act. The Reverse Stock Split is not intended to modify the rights of existing
stockholders in any material respect.

If the Reverse Stock Split Proposal is approved by our stockholders
and the Reverse Stock Split is effected, up to every 500 shares of our outstanding Common Stock would be combined and reclassified into
one share of Common Stock. Notwithstanding approval of the Reverse Stock Split Proposal by our stockholders, the Board will have the sole
authority to elect whether or not and when to amend our Charter to effect the Reverse Stock Split. If the Reverse Stock Split Proposal
is approved by our stockholders, the Board will make a determination as to whether effecting the Reverse Stock Split is in the best interests
of